Clinical trial NCT03572647: Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.
Official title: Randomized Clinical Study for Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax, Marketed by the Blausiegel Laboratory, Compared to Drug Eprex, Produced by Janssen-Cilag Laboratory, in Healthy Subjects.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Renal Insufficiency, Chronic
Keywords: Erythropoeitin
Chronic kidney disease
Anaemia
Lead sponsor: Azidus Brasil
Sponsor class: INDUSTRY
Collaborators: name: Blau Farmaceutica S.A.
First posted: 2018-06-28
Enrollment: 40
Sex: MALE
Minimum age (years): 20
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The epoetin is a glycoprotein and endogenous hormone, which is primarily synthesized by specific epithelial cells lining the kidney peritubular capillaries, and regulates continuous formation of red blood cells. This is a pharmacokinetics and pharmacodynamics study, in which each subject will receive the investigational product in different periods, as randomisation (Teste or Comparator). The evaluation of the profile included serum dosage of medications and reticulocyte count in peripheral blood.

Detailed description: This a prospective randomized and crossover study for evaluation of pharmacokinetics and pharmacodynamics of two epoetins formulations. The subjects will receive in each confinement period 4000 IU one of the investigational product subcutaneously, according to randomisation, separated by a washout period of 4 weeks. The evaluation of the profile between products included serum dosage of medications and reticulocyte count in peripheral blood. Safety evaluation data will include report od all adverse events (including type, frequency, intensity, seriousness, severity and action taken related to the investigational product study).

Eligibility criteria: Inclusion Criteria:

* Confirm the voluntary participation and agree to all the purposes of the study by signing and dating the IC in two ways;
* Being male, aged between 20 and 55 years, clinically healthy;
* BMI between 18 and 25;
* Results of examination of hemoglobin between 13.8 and 15.4 g / dL and hematocrit between 41% and 49%;
* Results of VCM, HBMC, platelets and leukocytes within the normal range:

VCM = Between 82 to 98. Among the HBMC = 26 to 34. Among the platelets = 150,000 to 400,000 units per mL. Among the WBC = 3,500 to 10,500 units per mL and without cellular atypia.

* Serum ferritin = Male between 36 to 262 mcg / L and women between 24 to 155 mcg / L;
* Reticulocyte count in peripheral blood ≤ 3%;
* Serum erythropoietin less than 30 mIU / mL.

Exclusion Criteria:

* Participation in clinical trials in the 12 months preceding the survey;
* Presence of iron deficiency anemia;
* Presence of pulmonary diseases, cardiovascular, neurological, endocrine, gastrointestinal, genitourinary or other systems;
* Acute disease in the period of 07 days prior to inclusion;
* Chronic administration of medication to determine, such as high blood pressure;
* Hormone therapy in the period of 02 months prior to inclusion;
* Administration of any drug in the 02 weeks prior to inclusion;
* A history of autoimmune anemia or hereditary;
* research subjects with a history of chronic bleeding;
* research subjects with a history of acute bleeding in the last 30 days;
* History of sensitivity to biological products derived from mammals, albumin, or any component of the formulation;
* History of or current use at least 12 months of tobacco;
* Current or previous history (less than 12 months) of illicit drug use;
* previous therapy with erythropoietin;
* albumin below 3.5 g / dl or greater than 4.8 g / dL;
* Signs or clinical history of bone marrow aplasia;
* History of liver disease and clinical or laboratory;
* History of renal disease and clinical or laboratory.

Primary outcomes:
measure: Pharmacokinetic - rHuEPO concentration.
timeFrame: Before administration (Time 0 hour) and after time 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 11 hours, 12 hours, 13 hours, 18 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours and 120 hours administration.
measure: Pharmacodynamics - Absolute Reticulocyte Count.
timeFrame: Before administration (Time 0 hour) and after Time 4 hours, 8 hours, 12 hours, 24 hours, 36 hours, 48 hours, 72 hours, 96 hours, 120 hours, 144 hours, 168 hours, 192 hours, 216 hours, 240 hours and 576 hours administration.
Secondary outcomes:
Other outcomes:
Locations:
city: Valinhos
country: Brazil
facility: LAL Clínica Pesquisa e Desenvolvimento Ltda.
state: São Paulo
Study officials:
affiliation: LAL Clinica Pesquisa e Desenvolvimento Ltda
name: Alexandre Frederico, PI
role: PRINCIPAL_INVESTIGATOR
References: